跳至主要内容
临床试验/NCT07223515
NCT07223515进行中(未招募)不适用

Effectiveness of Four Amniotic Membrane-based Skin Substitute Allografts Added to Standard Care in Chronic Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers (HEAL-4): A Multi-Site Real-World Study

Dynamic Medical Services dba Acesso Biologics2 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2025年10月24日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
2,000
试验地点
2
主要终点
Complete wound closure at 12 Weeks

研究概览

简要总结

This retrospective multi-site observational cohort study uses electronic health records (EHR) from U.S. wound care centers to evaluate the effectiveness of four amniotic membrane allografts (Acesso DL, Acesso TL, Neostim DL, Neostim TL) when added to standard wound care for diabetic foot ulcers (DFU), venous leg ulcers (VLU), and pressure ulcers (PU). The primary endpoint is complete wound closure by 12 weeks. Secondary outcomes include time-to-closure, ≥50% wound-area reduction at 4 weeks, wound-related complications (infection, hospitalization, emergency department visits, and major/minor amputation).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults ≥18; DFU/VLU/PU; sufficient observability

排除标准

  • Non-study advanced biologic product use within 60 days pre-index; insufficient follow-up

结局指标

主要结局

Complete wound closure at 12 Weeks

时间窗: From index visit to 12 weeks post-index

Proportion of index wounds with 100% epithelialization, no drainage or dressings; confirmation on ≥1 follow-up within 60 days

次要结局

  • Time to complete wound closure(From index visit up to 24 months post-index)
  • ≥50% wound area reduction at 4 weeks(From index visit to 4 weeks post-index)
  • Wound-related complications(From index visit up to 24 months post-index)

研究者

发起方
Dynamic Medical Services dba Acesso Biologics
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验